Background. Totally implantable intravenous ports (TIVAPs) are mostly used for long-term intravenous infusion therapy in cancer patients and can be left in the body for long periods of time for easy management, making them a simple and safe infusion device. Although the risks associated with long-term retention of fully implantable IV ports are less than those associated with other intravenous catheters, various complications may still occur at the time of implantation or during long-term use. Purpose. To provide a scientific basis for clinical reduction of implantable intravenous port-associated infection complications by studying the risk factors for catheter-associated infection complications in patients applying implantable intravenous ports. Methods. A retrospective study was conducted on oncology patients treated with TIVAP at our hospital between January 2017 and November 2021, with a review of patients who were unplanned for extubation. Their demographic data, underlying disease status, and surgery-related data were counted to summarize and analyze the complications and related influencing factors of implantation and postimplantation. Results. A total of 70 individuals with a mean age of 56.49 ± 12.19 years were included in the study. Among them, 39 were male and 64 had the highest percentage of epithelial tumors, followed by tumors of the lymphopoiesis system and mesenchymal tumors with 4 and 2 cases, respectively. Forty-eight of these patients did not have their ports removed as planned due to the occurrence of catheter-related hematogenous infections. In univariate analysis, BMI and neutropenia were risk factors for catheter-associated infections. In the multivariate analysis, BMI (OR = 1.38, 95% CI: 1.07–1.78, ) was an independent risk factor for catheter-associated infections. Conclusions. The overall complication rate of fully implanted intravenous ports was high, but most complications improved with symptomatic management, and no deaths due to port complications were identified. Infection was the most common complication, with catheter-associated bloodstream infection being the most common cause of unplanned port extraction. Patients with a higher BMI were at high risk of developing implantable IV port-associated infections, which may be an independent risk factor for implantable IV port-associated infections.

中文翻译：

---

肿瘤患者完全植入式静脉通路意外拔管时导管相关感染的危险因素


背景。完全植入式静脉输液港（TIVAP）多用于癌症患者的长期静脉输液治疗，可长期留在体内，便于管理，是一种简单、安全的输液装置。尽管长期保留完全植入式静脉输液港的风险低于其他静脉导管，但在植入时或长期使用过程中仍可能出现各种并发症。目的。通过研究植入式静脉输液港患者导管相关感染并发症的危险因素，为临床减少植入式静脉输液港相关感染并发症提供科学依据。方法。对2017年1月至2021年11月期间在我院接受TIVAP治疗的肿瘤患者进行回顾性研究，对计划外拔管的患者进行回顾性研究。统计其人口学资料、基础疾病状况以及手术相关数据，总结分析植入及植入后的并发症及相关影响因素。结果。该研究共有 70 名个体，平均年龄为 56.49 ± 12.19 岁。其中，男性39例，上皮性肿瘤64例，比例最高，其次是淋巴细胞生成系统肿瘤4例，间叶质肿瘤2例。其中 48 名患者由于发生导管相关的血行感染而没有按计划切除输液港。在单变量分析中，BMI和中性粒细胞减少症是导管相关感染的危险因素。在多变量分析中，BMI（OR = 1.38，95% CI：1。07–1.78, ）是导管相关感染的独立危险因素。结论。完全植入静脉输液港的总体并发症发生率很高，但大多数并发症通过对症治疗得到改善，并且没有发现因输液港并发症导致的死亡。感染是最常见的并发症，导管相关的血流感染是意外拔管的最常见原因。 BMI较高的患者发生植入式静脉输液港相关感染的风险较高，这可能是植入式静脉输液港相关感染的独立危险因素。